BOSTON, MA- Valo Health, LLC, a technology company that is working to transform the drug discovery and development process, announced the opening of a new state-of-the-art laboratory space in Lexington, Massachusetts.
Valo’s Lexington lab, which replaces the company’s Watertown facility, is a 30,000-foot, state-of-the-art research facility that will accommodate close to 50 Valo scientists who will work throughout six integrated and dedicated labs, including state-of-the-art capabilities in bioautomation, DNA-encoded libraries, high throughput biology, and disease biology for neurodegenerative, oncology and cardiovascular teams.
“Our new state-of-the-art Lexington lab will accelerate drug discovery and development through fully integrated technology and data, increasing efficiency and the self-reinforcing nature of our insights,” said Jonathan O’Connell, Vice President, Valo Early Discovery and Technology. “We are proud to be able to move forward and open our new facility, despite the unprecedented challenges of the COVID-19 pandemic that created many situational obstacles to continued growth across every industry. These challenges furthered our resolve to continue reimagining drug development to create solutions to some of the world’s most challenging diseases.”
Valo is looking forward to opening the Lexington lab space, which will allow its scientists to continue the work of reimagining drug development uninterrupted during the COVID-19 pandemic. In addition to the CDC’s COVID-19 guidelines, Valo has incorporated extra safety measures into the infrastructure such as temperature checks on entry, routine COVID-19 testing, as well as permanently partitioned desks and workspaces.
